FDA Drug recall D-0898-2017
Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx only, Hospira, Inc
- FDA Drug
- Class II
- terminated
- Published 2017-06-21
On 2017-06-21 the FDA classified a Class II recall of Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx only, Hospira, Inc by Hospira A Pfizer, citing GMP Deviation; A foreign stopper was observed during packaging of a lot of product.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0898-2017 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2017-05-18 |
| Published | 2017-06-21 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Hospira A Pfizer |
| Distribution | US |
Product
Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx only, Hospira, Inc. Lake Forest, IL --- NDC 0409-3375-04
Reason
GMP Deviation; A foreign stopper was observed during packaging of a lot of product.
Identifiers
| ndc | 0409-3375-14 |
|---|---|
| ndc | 0409-3375-04 |
| ndc | 0409-1443-14 |
| ndc | 0409-1443-04 |
| code_info | 720503A, 720603A (Canada only) |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0898-2017%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.